Overview

Expanded Access Program With Nivolumab to Treat Melanoma

Status:
No longer available
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Nivolumab